| Comparison of oral cefpodoxime proxetil and cefaclor in the treatment of skin and soft tissue infections. | |
| | |
MedLine Citation:
|
PMID: 8467623 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
This multicenter, randomized, double-blind study was designed to compare the safety and efficacy of cefpodoxime proxetil and cefaclor in the treatment of skin and soft tissue infections. Patients were aged > or = 12 years with acute (< or = 7 days duration), single-site skin or skin-structure infections. The 7- to 10-day treatment regimens were cefpodoxime proxetil (400 mg cefpodoxime) orally with food twice a day with cefaclor-matched placebo (orally, fasting, three times a day); or cefaclor (Ceclor; 500 mg anhydrous equivalent) orally, fasting, three times a day, with cefpodoxime-matched placebo (orally with food twice a day). Clinical progress and cultures were evaluated upon admission to the study; on study days 7-10 and 15-18; and 2-3 weeks after treatment. Cefpodoxime had lower minimum inhibitory concentrations against the majority of Staphylococcus species than did cefaclor. Both treatments were highly effective (99% pathogen eradication and 86% cure rate). These high eradication rates were not unexpected in this study of minor infections in which patients with resistant pathogens were excluded. Cefaclor had a higher failure rate [2 (4%) of 57], than did cefpodoxime [2 (1%) of 139; p not significant]. Most patients in both groups completed treatment as planned: 185 (74%) of 249 cefpodoxime-treated patients and 91 (75%) of 122 cefaclor-treated patients. Both treatments were well tolerated and considered safe and effective in the treatment of skin and skin structure infections. However, the twice-a-day dosing regimen for cefpodoxime proxetil compared with the three-times-a-day regimen for cefaclor may result in better patient compliance. |
| | |
Authors:
|
D L Stevens; F Pien; M Drehobl |
Related Documents
:
|
23426153 - An outcome study for ulnar neuropathy at the elbow: a multicenter study by the sun stud... 10566563 - Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary si... 22418633 - Evaluation of postprescription review and feedback as a method of promoting rational an... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Diagnostic microbiology and infectious disease Volume: 16 ISSN: 0732-8893 ISO Abbreviation: Diagn. Microbiol. Infect. Dis. Publication Date: 1993 Feb |
Date Detail:
|
Created Date: 1993-05-12 Completed Date: 1993-05-12 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8305899 Medline TA: Diagn Microbiol Infect Dis Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 123-9 Citation Subset: IM |
Affiliation:
|
VA Medical Center, Boise, Idaho 83702. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Adult Bacterial Infections / drug therapy Cefaclor / administration & dosage, adverse effects, therapeutic use* Ceftizoxime / administration & dosage, adverse effects, analogs & derivatives*, therapeutic use Connective Tissue Diseases / drug therapy* Double-Blind Method Drug Administration Schedule Drug Resistance, Microbial Female Humans Male Middle Aged Prodrugs / administration & dosage, adverse effects, therapeutic use* Safety Skin Diseases, Bacterial / drug therapy* Staphylococcal Infections / drug therapy |
| Chemical | |
Reg. No./Substance:
|
0/Prodrugs; 53994-73-3/Cefaclor; 68401-81-0/Ceftizoxime; 87239-81-4/cefpodoxime proxetil |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Species identification and determination of high-level aminoglycoside resistance among enterococci. ...
Next Document: In vitro activity of rifaximin, a topical rifamycin derivative, against Chlamydia trachomatis.